MC2 Therapeutics launches psoriasis cream in US

The pharmaceutical firm has worked with partner Epi Health to launch Wynzora on the US market, where it was authorized as a treatment for psoriasis last year.
Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR
Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Just under a year after MC2 Therapeutics received approval from the FDA for its psoriasis cream Wynzora, the treatment has been launched on the US market, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading